Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

Current Opinion in Immunology

Volumn 20, Issue 4, 2008, Pages 431-435

  Aarden, Lucien ^a   Ruuls, Sigrid R ^b   Wolbink, Gertjan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CHIMERIC ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; LOW DRUG DOSE; RADIOIMMUNOASSAY; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48549102501     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.06.011     Document Type: Review

References (31)

1. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Bijl H., and Woody J.N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344 (1994) 1125-1127
2. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
3. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
4. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., Teoh L.A., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
5. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., and Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008) 244-279. Extensive and complete review covering all aspects of anti-TNF therapy.
6. Shankar G., Shores E., Wagner C., and Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 24 (2006) 274-280
7. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., and Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
8. Hwang W.Y., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
9. Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34 (2005) 19-22
10. Zack D.J., Stempniak M., Wong A.L., and Weisbart R.H. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J Immunol 155 (1995) 5057-5063
11. Osterland C.K., Harboe M., and Kunkel H.G. Anti-gamma-globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang 8 (1963) 133-152
12. Williams R.C., and Kunkel H.G. Observations on antigamma globulin factors in human sera and antibodies against autologous gamma globulins produced in rabbits. Ann NY Acad Sci 124 (1965) 860-864
13. Persselin J.E., and Stevens R.H. Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest 76 (1985) 723-730
14. Zhou H., Jang H., Fleischmann R.M., Bouman-Thio E., Xu Z., Marini J.C., Pendley C., Jiao Q., Shankar G., Marciniak S.J., et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47 (2007) 383-396
15. Aalberse R.C., and Schuurman J. IgG4 breaking the rules. Immunology 105 (2002) 9-19
16. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 (2007) 1554-1557
17. Aalberse R.C., van der Gaag R., and van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 130 (1983) 722-726
18. Bendtzen K. Immunogenicity of anti-TNF antibodies. In: van de Weert M., and Møller E.H. (Eds). Immunogenicity of Biopharmaceuticals (2008), Springer 189-203
19. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T., Stapel S., Tak P.P., Aarden L., and Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 711-715. First demonstration in rheumatoid arthritis patients that antibodies to the TmAb interfere with clinical efficacy.
20. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., and Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54 (2006) 3782-3789
21. de Vries M.K., Wolbink G.J., Stapel S.O., de Vrieze H., van Denderen J.C., Dijkmans B.A., Aarden L.A., and van der Horst-Bruinsma I.E. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66 (2007) 1252-1254
22. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., and Wolbink G.J. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66 (2007) 921-926
23. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, Van Denderen JC, Dijkmans BA, Wolbink GJ: Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (AS). Ann Rheum Dis 2008, in press.
24. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 (2004) 2645-2668
25. Van der Laken C.J., Voskuyl A.E., Roos J.C., Stigter van Walsum M., de Groot E.R., Wolbink G., Dijkmans B.A., and Aarden L.A. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66 (2007) 253-256. In this study the fate of 99Tc-labeled infliximab is studied in RA patients with and without HACAs.
26. Patton A., Mullenix M.C., Swanson S.J., and Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 304 (2005) 189-195
27. Lofgren J.A., Wala I., Koren E., Swanson S.J., and Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods 308 (2006) 101-108
28. Bourdage J.S., Cook C.A., Farrington D.L., Chain J.S., and Konrad R.J. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods 327 (2007) 10-17
29. Smith H.W., Butterfield A., and Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol 49 (2007) 230-237
30. Sickert D., Kroeger K., Zickler C., Chokote E., Winkler B., Grenet J.M., Legay F., and Zaar A. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J Immunol Methods 334 (2008) 29-36
31. Flendrie M., Creemers M.C., and van Riel P.L. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) 46 (2007) 146-149